Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote & News

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

Alex036 Mar. 20 at 2:19 PM

$ARMP Lesson #3 completed.Waiting for the next one.

2 · Reply

DragonAlgo Mar. 20 at 10:29 AM

🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 🔗 https://dragonalgo.com

0 · Reply

Trapped Mar. 17 at 12:42 PM

$ARMP undervalued for sure

0 · Reply

DragonAlgo Mar. 17 at 5:03 AM

0 · Reply

Trapped Mar. 13 at 5:31 PM

$ARMP 15 coming

0 · Reply

DragonAlgo Mar. 13 at 10:26 AM

1 · Reply

SuperGreenToday Mar. 11 at 9:34 PM

$ARMP Share Price: $11.43 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.91 – $1.11 Potential Upside: 68% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Trapped Mar. 10 at 12:09 AM

$ARMP 56k shares traded and it’s up $1 plus. this is going to explode with proper FDA. news …hold on

0 · Reply

Trapped Mar. 8 at 6:26 PM

$ARMP Armata Pharmaceuticals, Inc. : H.C. Wainwright raises target to $15 from $9 *

0 · Reply

Trapped Mar. 4 at 2:07 PM

$ARMP any good news from FDA will ramp up this stock big time. buy and hold your positions. best way

0 · Reply

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Feb 23, 2026, 7:00 AM EST - 26 days ago

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Jan 13, 2026, 7:00 AM EST - 2 months ago

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Nov 18, 2025, 7:00 AM EST - 4 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 12, 2025, 4:05 PM EST - 4 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 4 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 5 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 5 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 10 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 11 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 11 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 4 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

Alex036 Mar. 20 at 2:19 PM

$ARMP Lesson #3 completed.Waiting for the next one.

2 · Reply

DragonAlgo Mar. 20 at 10:29 AM

0 · Reply

Trapped Mar. 17 at 12:42 PM

$ARMP undervalued for sure

0 · Reply

DragonAlgo Mar. 17 at 5:03 AM

0 · Reply

Trapped Mar. 13 at 5:31 PM

$ARMP 15 coming

0 · Reply

DragonAlgo Mar. 13 at 10:26 AM

1 · Reply

SuperGreenToday Mar. 11 at 9:34 PM

0 · Reply

Trapped Mar. 10 at 12:09 AM

$ARMP 56k shares traded and it’s up $1 plus. this is going to explode with proper FDA. news …hold on

0 · Reply

Trapped Mar. 8 at 6:26 PM

$ARMP Armata Pharmaceuticals, Inc. : H.C. Wainwright raises target to $15 from $9 *

0 · Reply

Trapped Mar. 4 at 2:07 PM

$ARMP any good news from FDA will ramp up this stock big time. buy and hold your positions. best way

0 · Reply

History101 Mar. 2 at 8:53 PM

$ARMP a big day for me, my ARMP position is now up over 100%...awesome. GLTALs!!

1 · Reply

Trapped Mar. 2 at 3:32 PM

$ARMP $15 this month

0 · Reply

Alex036 Feb. 26 at 4:38 PM

$ARMP This train is not intended for regular passengers (ordinary SHs), but only for train owners (MMs). Once MMs achieve their personal ultimate goals, they will kick everyone off the train.

1 · Reply

Trapped Feb. 26 at 4:02 PM

$ARMP the stock is worth a lot more … bottom line

0 · Reply

Watchingnow Feb. 26 at 1:26 PM

$ARMP FDA news means what exactly? Its obviously not the go ahead to market the drug. Forgive the ignorance. Is this a first step in accelerated approval? Whats the new timeline? Thanks

0 · Reply

Trapped Feb. 25 at 5:59 PM

$ARMP so we are currently at 439 million market cap. hmmmm what would be a main stream drug with today in annual sales?? 1/2 billion. you can do the math. that’s 5 x the pps. hello $50.

0 · Reply

History101 Feb. 24 at 9:19 PM

$IBRX $ARMP ARMP finished strong at $11.86, edging past IBRX at $11.55

1 · Reply

Trapped Feb. 24 at 8:26 PM

$ARMP

1 · Reply

topstockalerts Feb. 24 at 7:31 PM

$ARMP super tight structure and not a lot of eyes on it yet. When these start getting real volume, they don’t move in small increments. Any corporate update and this can reprice quick. Feels like a sleeper.

0 · Reply

Trapped Feb. 24 at 6:42 PM

$ARMP just the beginning!

0 · Reply

History101 Feb. 24 at 5:43 PM

$IBRX LOL my IBRX and $ARMP are neck & neck for highest close today, both in the mid 11s and both skyrocketing today

0 · Reply

sh3r1ock Feb. 24 at 5:21 PM

$ARMP whoaaa

0 · Reply

Market Cap	310.92M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.53

Volume	57,400
Avg Vol	51,568
Day's Range	N/A - N/A
Shares Out	36.41M
Stochastic %K	21%
Beta	1.30
Analysts	Strong Sell
Price Target	$15.00